DYV700

About Dyve Biosciences

Dyve Biosciences is pioneering a new class of therapies by using its DMAX transdermal delivery platform to systemically administer pH-modulating agents that are unsuitable for oral or injectable routes. The company's core innovation addresses the challenge of altering the acidic tumor microenvironment (TME) and other disease sites, which is known to drive cancer progression, immune evasion, and inflammation. With a completed Phase 2 proof-of-concept study and a pipeline targeting oncology and immunology, Dyve is positioning transdermal delivery as a legitimate third route for systemic drug administration. The company is led by an experienced team and is actively seeking partnerships to expand its therapeutic horizon.

Therapeutic Areas